Former General Counsel · Verona Pharma plc (VRNA)

Claire Poll

FY2024 is the first fiscal year CompBrief holds for Claire Poll as a named executive officer of Verona Pharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$326,023

Salary $326,023Stock awards $0

5th of 5 named executive officers at Verona Pharma by FY2024 total.

5 named officers on file for Verona Pharma, FY2024

Claire Poll’s pay file — $29

  • 1 fiscal year of pay, line by line
  • VRNA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Verona Pharma’s whole pay program stands against its peers

  • Verona Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRNA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 18, 2025 (DEF 14A).

Free

Get Claire Poll’s full pay file as a PDF — free

More than this page: up to 10 years of Claire’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Claire Poll compensation by year

Verona Pharma Summary Compensation Table · the one fiscal year held
In US dollars, as Verona Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$326,023
Bonus$0
Stock awards$0
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$326,023

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Verona Pharma plc DEF 14A filed March 18, 2025, accession 0001104659-25-025050, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Verona Pharma plc filed document, accession 0001104659-25-025050. Every figure is read from that document and cited to the page and table it appears in. Filed March 18, 2025.

Verona Pharma’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
David ZaccardelliPresident and Chief Executive Officer$19,456,473
Mark HahnChief Financial Officer$19,005,415
Andrew FisherGeneral Counsel$10,821,932
Kathleen RickardChief Medical Officer$7,509,563
Claire Poll · this pageFormer General Counsel$326,023

The full Verona Pharma compensation record

free company brief

This page is one person within Verona Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Verona Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Claire Poll's compensation dossier · One-time report. No refunds.